Scientists Uncover Hidden Pathway That Drives Cholesterol Buildup in the Liver
A newly discovered Ral GTPase pathway degrades LDLR receptors in response to dietary cholesterol — and blocking it may lower LDL.
Summary
Researchers at UC San Diego have identified a previously unknown molecular pathway that explains why eating high-cholesterol foods raises LDL levels in the blood. When you consume excess dietary cholesterol, a set of proteins called Ral GTPases become activated in liver cells. This triggers a chain reaction that shuttles LDL receptors — the proteins responsible for clearing cholesterol from the blood — to cellular waste compartments called lysosomes, where an enzyme called cathepsin A destroys them. With fewer LDL receptors available, cholesterol accumulates in the bloodstream. Crucially, this process operates independently of PCSK9, the target of currently approved cholesterol-lowering drugs. Blocking cathepsin A pharmacologically restored LDL receptor levels and improved cholesterol clearance in experimental models, pointing toward an entirely new drug target for cardiovascular disease.
Detailed Summary
Cardiovascular disease remains the world's leading killer, and elevated LDL cholesterol is one of its most powerful risk factors. While statins and PCSK9 inhibitors have transformed treatment, many patients remain inadequately controlled, and the cellular mechanisms linking diet to cholesterol metabolism are still incompletely understood. This study addresses a critical gap by identifying a new molecular circuit that connects dietary cholesterol intake directly to the destruction of the liver's LDL receptors.
The research team investigated how liver cells sense and respond to chronically high dietary cholesterol. They found that excess extracellular cholesterol activates the RAS signaling protein, which in turn switches on a family of small GTPase proteins called Ral. Activated Ral recruits an endocytic complex — RalBP1 and REPS1 — that intercepts LDL receptors (LDLR) during recycling and reroutes them to lysosomes for degradation. This process is entirely independent of PCSK9 and does not involve changes in gene transcription.
Once LDLR is delivered to lysosomes, a protease called cathepsin A (CTSA) degrades it. Ral activation also redirects CTSA trafficking — pulling it into lysosomes where it matures and becomes active, rather than allowing it to be secreted extracellularly. This dual mechanism amplifies LDLR destruction. Genetic deletion of the Ral regulator RalGAPB in hepatocytes confirmed that constitutive Ral activity reduces LDLR levels and impairs cholesterol clearance in vivo. Importantly, human genetic variants in this pathway associate with altered cholesterol levels, validating clinical relevance.
Pharmacological inhibition of CTSA activity restored hepatic LDLR levels and enhanced cholesterol clearance, suggesting a novel druggable target for hypercholesterolemia independent of existing therapies.
This work opens an exciting therapeutic avenue, particularly for patients unresponsive to statins or PCSK9 inhibitors. Limitations include reliance on the abstract alone, meaning full mechanistic and in vivo details cannot be assessed.
Key Findings
- Dietary cholesterol activates Ral GTPases in liver cells, triggering LDLR destruction independently of PCSK9 or gene regulation.
- Ral recruits the RalBP1-REPS1 complex to reroute LDL receptors to lysosomes instead of recycling them to the cell surface.
- The lysosomal protease cathepsin A degrades LDLR; Ral activation concentrates cathepsin A in lysosomes to amplify this effect.
- Human genetic variants in this Ral pathway significantly associate with altered blood cholesterol levels.
- Pharmacological inhibition of cathepsin A restored LDLR levels and improved cholesterol clearance in experimental models.
Methodology
The study used hepatocyte cell models, genetic manipulation (RalGAPB deletion, constitutively active Ral mutants), and pharmacological inhibitors to dissect the pathway. Human genetic variant analysis linked pathway genes to circulating cholesterol levels. Full in vivo experimental details are not assessable from the abstract alone.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access — detailed methods, full datasets, and supplementary findings cannot be evaluated. The pharmacological CTSA inhibition results require validation in robust in vivo and ultimately human models before clinical conclusions can be drawn. The degree to which this pathway contributes to LDL elevation relative to PCSK9-mediated mechanisms in humans remains to be quantified.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: